Autoimmune giant cell myocarditis – clinical characteristics, experimental models and future treatments

Bibliography

• Cooper LT. Myocarditis. N Engl J Med 2009;360:1526-38
   PubMed Web of Science ®Google Scholar
• Blauwet LA, Cooper LT. Myocarditis. Prog Cardiovasc Dis 2010;52:274-88
   PubMed Web of Science ®Google Scholar
• Kodama M, Oda H, Okabe M, Early and long-term mortality of the clinical subtypes of myocarditis. Jpn Circ J 2001;65:961-4
   PubMedGoogle Scholar
• Okura Y, Dec GW, Hare JM, A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol 2003;41:322-9
   PubMed Web of Science ®Google Scholar
• Davies MJ, Pomerance A, Teare RD. Idiopathic giant cell myocarditis – a distinctive clinico-pathological entity. Br Heart J 1975;37:192-5
   PubMedGoogle Scholar
• Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis – natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 1997;336:1860-6
   PubMed Web of Science ®Google Scholar
• Kilgallen CM, Jackson E, Bankoff M, A case of giant cell myocarditis and malignant thymoma: a postmortem diagnosis by needle biopsy. Clin Cardiol 1998;21:48-51
   PubMedGoogle Scholar
• Daniels PR, Berry GJ, Tazelaar HD, Giant cell myocarditis as a manifestation of drug hypersensitivity. Cardiovasc Pathol 2000;9:287-91
   PubMedGoogle Scholar
• Frustaci A, Chimenti C, Calabrese F, Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 2003;107:857-63
   PubMed Web of Science ®Google Scholar
• Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 2009;30:1995-2002
   PubMed Web of Science ®Google Scholar
• Aziz KU, Patel N, Sadullah T, Acute viral myocarditis: role of immunosuppression: a prospective randomised study. Cardiol Young 2010;20:509-15
   PubMed Web of Science ®Google Scholar
• Allanore Y, Vignaux O, Arnaud L, Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging. Ann Rheum Dis 2006;65:249-52
   PubMed Web of Science ®Google Scholar
• Mason JW, O'Connell JB, Herskowitz A, A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995;333:269-75
   PubMed Web of Science ®Google Scholar
• Cooper LT Jr, Hare JM, Tazelaar HD, Giant Cell Myocarditis Treatment Trial Investigators: usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008;102:1535-9
   PubMed Web of Science ®Google Scholar
• Menghini VV, Savcenko V, Olson LJ, Combined immunosuppression for the treatment of idiopathic giant cell myocarditis. Mayo Clin Proc 1999;74:1221-6
   PubMed Web of Science ®Google Scholar
• Kodama M, Matsumoto Y, Fujiwara M, A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 1990;57:250-62
   PubMedGoogle Scholar
• Smith SC, Allen PM. Myosin-induced acute myocarditis is a T cell-mediated disease. J Immunol 1991;147:2141-7
   PubMed Web of Science ®Google Scholar
• Liao L, Sindhwani R, Rojkind M, Antibody-mediated autoimmune myocarditis depends on genetically determined target organ sensitivity. J Exp Med 1995;181:1123-31
   PubMed Web of Science ®Google Scholar
• Afanasyeva M, Wang Y, Kaya Z, Interleukin-12 receptor/STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-gamma-independent pathway. Circulation 2001;104:3145-51
   PubMed Web of Science ®Google Scholar
• Afanasyeva M, Wang Y, Kaya Z, Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype. Am J Pathol 2001;159:193-203
   PubMed Web of Science ®Google Scholar
• Cihakova D, Barin JG, Afanasyeva M, Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am J Pathol 2008;172:1195-208
   PubMed Web of Science ®Google Scholar
• Kaya Z, Dohmen KM, Wang Y, Cutting edge: a critical role for IL-10 in induction of nasal tolerance in experimental autoimmune myocarditis. J Immunol 2002;168:1552-6
   PubMed Web of Science ®Google Scholar
• Eriksson U, Kurrer MO, Sonderegger I, Activation of dendritic cells through the role of cardiac troponins and autoimmunity in the pathogenesis of myocarditis and heart failure 87 interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis. J Exp Med 2003;197:323-31
   PubMedGoogle Scholar
• Eriksson U, Kurrer MO, Schmitz N, Interleukin-6-deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3. Circulation 2003;107:320-5
   PubMedGoogle Scholar
• Rangachari M, Mauermann N, Marty RR, T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med 2006;203:2009-19
   PubMed Web of Science ®Google Scholar
• Fairweather D, Kaya Z, Shellam GR, From infection to autoimmunity. J Autoimmun 2001;16:175-86
   PubMed Web of Science ®Google Scholar
• Kaya Z, Afanasyeva M, Wang Y, Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat Immunol 2001;2:739-45
   PubMed Web of Science ®Google Scholar
• Hanawa H, Kodama M, Zhang S, An immunosuppressant compound, FK-506, prevents the progression of autoimmune myocarditis in rats. Clin Immunol Immunopathol 1992;62:321-6
   PubMedGoogle Scholar
• Zhang S, Kodama M, Hanawa H, Effects of cyclosporine, prednisolone and aspirin on rat autoimmune giant cell myocarditis. J Am Coll Cardiol 1993;21:1254-60
   PubMedGoogle Scholar
• Suzuki J, Ogawa M, Futamatsu H, A Cyclooxygenase-2 inhibitor alters Th1/Th2 cytokine balance and suppresses autoimmune myocarditis in rats. J Mol Cell Cardiol 2006;40:688-95
   PubMedGoogle Scholar
• Wakizono-Azuma R, Suzuki J, Ogawa M, HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation. Cardiovasc Res 2004;64:412-20
   PubMedGoogle Scholar
• Hishikari K, Watanabe R, Ogawa M, Early treatment with clarithromycin attenuates rat autoimmune myocarditis via inhibition of matrix metalloproteinase activity. Heart 2010;96:523-7
   PubMed Web of Science ®Google Scholar
• Suzuki J, Ogawa M, Futamatsu H, Tea catechins improve left ventricular dysfunction, suppress myocardial inflammation, fibrosis, and alter cytokine expression in rat autoimmune myocarditis. Eur J Heart Fail 2007;9:152-9
   PubMed Web of Science ®Google Scholar
• Futamatsu H, Suzuki J, Koga N, A CCR1 antagonist prevents the development of experimental autoimmune myocarditis in association with T cell inactivation. J Mol Cell Cardiol 2006;40:853-61
   PubMed Web of Science ®Google Scholar
• Suzuki J, Ogawa M, Muto S, The effects of pharmacological PAI-1 inhibition on thrombus formation and neointima formation after arterial injury. Expert Opin Ther Targets 2008;12:783-94
   PubMed Web of Science ®Google Scholar
• Suzuki J, Ogawa M, Muto S, A specific inhibitor of plasminogen activator inhibitor-1 suppresses rat autoimmune myocarditis. Expert Opin Ther Targets 2008;12:1313-20
   PubMed Web of Science ®Google Scholar
• Ngoc PB, Suzuki J, Ogawa M, The anti-inflammatory mechanism of prostaglandin E2 receptor 4 activation in rat experimental autoimmune myocarditis. J Cardiovasc Pharmacol 2011;57:365-72
   PubMedGoogle Scholar
• Hanawa H, Kodama M, Inomata T, Anti-alphabeta T cell receptor antibody prevents the progression of experimental autoimmune myocarditis. Clin Exp Immunol 1994;96:470-5
   PubMedGoogle Scholar
• Futamatsu H, Suzuki J, Kosuge H, Attenuation of experimental autoimmune myocarditis by blocking activated T cells through inducible costimulatory molecule pathway. Cardiovasc Res 2003;59:95-104
   PubMedGoogle Scholar
• Haga T, Suzuki J, Kosuge H, Attenuation of experimental autoimmune myocarditis by blocking T cell activation through 4-1BB pathway. J Mol Cell Cardiol 2009;46:719-27
   PubMedGoogle Scholar
• Yokoseki O, Suzuki J, Kitabayashi H, Cis element decoy against neculear factor-kappaB attenuates development of experimental autoimmune myocarditis in rats. Circ Res 2001;89:899-906
   PubMedGoogle Scholar
• Futamatsu H, Suzuki J Mizuno S, Hepatocyte growth factor ameliorates the progression of experimental autoimmune myocarditis: a potential role for induction of T helper 2 cytokines. Circ Res 2005;96:823-30
   PubMed Web of Science ®Google Scholar
• Okada H, Suzuki J, Futamatsu H, Attenuation of autoimmune myocarditis in rats by mesenchymal stem cell transplantation through enhanced expression of hepatocyte growth factor. Int Heart J 2007;48:649-61
   PubMedGoogle Scholar
• Chang H, Hanawa H, Yoshida T, Alteration of IL-17 related protein expressions in experimental autoimmune myocarditis and inhibition of IL-17 by IL-10–Ig fusion gene transfer. Circ J 2008;72:813-19
   PubMed Web of Science ®Google Scholar
• Ying H, Yang L, Qiao G, Cutting edge: CTLA-4–B7 interaction suppresses Th17 cell differentiation. J Immunol 2010;185:1375-8
   PubMed Web of Science ®Google Scholar
• Suzuki J, Isobe M, Morishita R, Effects of tea catechins on inflammation-related cardiovascular disease. Curr Immnol Rev 2009;5:167-74
   Google Scholar
• Kuriyama S, Shimazu T, Ohmori K, Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 2006;296:1255-65
   PubMed Web of Science ®Google Scholar
• Suzuki J, Ogawa M, Muto S, Effects of specific chemical suppressors of plasminogen activator inhibitor-1 in cardiovascular diseases. Expert Opin Investig Drugs 2011;20:255-64
   PubMed Web of Science ®Google Scholar
• Salliot C, Finckh A, Katchamart W, Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 2011;70:266-71
   PubMed Web of Science ®Google Scholar
• Suzuki J, Isobe M, Morishita R, Nucleic acid drugs for prevention of cardiac rejection. J Biomed Biotech 2009; published online 11 October 2009; doi:10.1155/2009/916514
   PubMedGoogle Scholar